Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.

Schwartz T, Stark A, Pang J, Awuah B, Kleer CG, Quayson S, Kingman S, Aitpillah F, Abantanga F, Jiagge E, Oppong JK, Osei-Bonsu E, Martin I, Yan X, Toy K, Adjei E, Wicha M, Newman LA.

Cancer. 2013 Feb 1;119(3):488-94. doi: 10.1002/cncr.27737. Epub 2012 Aug 28.

2.

Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.

Proctor E, Kidwell KM, Jiagge E, Bensenhaver J, Awuah B, Gyan K, Toy K, Oppong JK, Kyei I, Aitpillah F, Osei-Bonsu E, Adjei E, Ohene-Yeboah M, Brewer RN, Fondjo LA, Owusu-Afriyie O, Wicha M, Merajver S, Kleer C, Newman L.

Ann Surg Oncol. 2015 Nov;22(12):3831-5. doi: 10.1245/s10434-015-4455-x. Epub 2015 Mar 6.

PMID:
25743329
3.

Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.

Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S.

Cancer Sci. 2009 Jun;100(6):1062-8. doi: 10.1111/j.1349-7006.2009.01151.x. Epub 2009 Mar 9.

4.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
5.

Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer.

Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, Qian H, Xu B.

Int J Biol Markers. 2013 Dec 17;28(4):e357-64. doi: 10.5301/jbm.5000048.

PMID:
24338721
6.

Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.

DA Cruz Paula A, Marques O, Rosa AM, DE Fátima Faria M, Rêma A, Lopes C.

Anticancer Res. 2014 Mar;34(3):1427-34.

PMID:
24596390
7.

Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer.

Isfoss BL, Holmqvist B, Alm P, Olsson H.

Histopathology. 2012 Mar;60(4):617-33. doi: 10.1111/j.1365-2559.2011.04109.x. Epub 2012 Jan 19.

PMID:
22260461
8.

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.

Nalwoga H, Arnes JB, Wabinga H, Akslen LA.

Br J Cancer. 2010 Jan 19;102(2):369-75. doi: 10.1038/sj.bjc.6605488. Epub 2009 Dec 15.

9.

Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.

Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S.

Hum Pathol. 2013 Aug;44(8):1465-71. doi: 10.1016/j.humpath.2012.12.016. Epub 2013 Mar 1.

PMID:
23465277
10.

Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.

Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K.

Oncology. 2012;82(3):168-74. doi: 10.1159/000336078. Epub 2012 Mar 15.

PMID:
22433454
11.

Breast cancer stem cells and intrinsic subtypes: controversies rage on.

Nakshatri H, Srour EF, Badve S.

Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60. Review.

PMID:
19149630
12.

ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.

Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y, Sun Q.

Med Oncol. 2014 Mar;31(3):864. doi: 10.1007/s12032-014-0864-0. Epub 2014 Feb 12.

PMID:
24519209
13.

Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells.

Tsukabe M, Shimazu K, Morimoto K, Naoi Y, Kagara N, Shimoda M, Shimomura A, Maruyama N, Kim SJ, Noguchi S.

Oncology. 2013;85(4):248-56. doi: 10.1159/000355476. Epub 2013 Oct 29.

PMID:
24192633
14.

Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.

Heerma van Voss MR, van der Groep P, Bart J, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Feb;34(1):3-10. doi: 10.1007/s13402-010-0007-3. Epub 2011 Feb 19.

15.

BRCA1 regulates human mammary stem/progenitor cell fate.

Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS.

Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5. doi: 10.1073/pnas.0711613105. Epub 2008 Jan 29.

16.
17.

Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.

Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH.

Neoplasma. 2014;61(3):352-62.

PMID:
24824938
18.

High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas.

Madjd Z, Ramezani B, Molanae S, Asadi-Lari M.

Asian Pac J Cancer Prev. 2012;13(6):2973-8.

19.

Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.

Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.

20.

Aldehyde dehydrogenase 1: a specific cancer stem cell marker for human colorectal carcinoma.

Zhou F, Mu YD, Liang J, Liu ZX, Zhou D, Ning WL, Li YZ, Ding D, Zhang JF.

Mol Med Rep. 2015 May;11(5):3894-9. doi: 10.3892/mmr.2015.3195. Epub 2015 Jan 13.

PMID:
25585687
Items per page

Supplemental Content

Write to the Help Desk